Iambic Therapeutics CFO reports 190,160 common shares

Q: How many shares did IAM CFO Michael Secora report owning?

Michael Secora reported direct ownership of 190,160 common shares and 61,342 Series B-3 convertible preferred shares. Of the common shares, 23,770 were issued under an early-exercise provision and vest in full on January 1, 2027. The preferred shares automatically convert one-for-one into common stock immediately before completion of the initial public offering.

Q: What options did IAM CFO Michael Secora report?

He reported options covering 190,161 common shares at $7.31, expiring January 8, 2035, and options covering 9,508 common shares at $8.73, expiring March 3, 2036. The first option vests in 48 equal monthly installments beginning February 1, 2025; the second vests in 48 equal monthly installments beginning March 23, 2026.

Options covering 190,161 shares have a $7.31 exercise price and expire January 8, 2035; options covering 9,508 shares have an $8.73 exercise price and expire March 3, 2036.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Iambic Therapeutics, Inc. CFO & Chief Corp Dev Ofcr Michael Secora reported direct ownership of 190,160 common shares, including 23,770 shares issued under an early-exercise provision that vest in full on January 1, 2027. He also reported 61,342 Series B-3 convertible preferred shares, which automatically convert one-for-one into common stock immediately before completion of the company's initial public offering, and options covering 190,161 shares at $7.31 and 9,508 shares at $8.73.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Secora Michael

Role CFO & Chief Corp Dev Ofcr

Type	Security	Shares	Price	Value
holding	Series B-3 Convertible Preferred Stock ^F2	--	--	--
holding	Employee Stock Option (right to buy) ^F3	--	--	--
holding	Employee Stock Option (right to buy) ^F4	--	--	--
holding	Common Stock ^F1	--	--	--

Holdings After Transaction: Series B-3 Convertible Preferred Stock — 61,342 contracts (Direct); Employee Stock Option (right to buy) — 199,669 contracts (Direct); Common Stock — 190,160 shares (Direct)

Footnotes (4)

F1. Of the reported shares, 23,770 were issued pursuant to an early exercise provision and which vest in full on January 1, 2027.
F2. Each share of Series B-3 Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
F3. An option to purchase 380,322 shares was granted on January 8, 2025 and was exercised in part prior to the date on which the reporting person became subject to Section 16. The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest in 48 equal monthly installments beginning on February 1, 2025.
F4. The shares subject to the option vest in 48 equal monthly installments beginning on March 23, 2026.

Key Figures

Direct common shares: 190,160 shares Series B-3 convertible preferred shares: 61,342 shares Early-exercise shares: 23,770 shares +2 more

5 metrics

Direct common shares 190,160 shares Holding entry dated October 14, 2026

Series B-3 convertible preferred shares 61,342 shares Automatically convert one-for-one immediately before completion of the initial public offering

Early-exercise shares 23,770 shares Vest in full on January 1, 2027

Option underlying shares 190,161 shares Exercise price $7.31 per share; expiration January 8, 2035

Option underlying shares 9,508 shares Exercise price $8.73 per share; expiration March 3, 2036

Key Terms

early exercise provision, automatically convert, 48 equal monthly installments, initial public offering

4 terms

early exercise provision technical

"issued pursuant to an early exercise provision"

automatically convert technical

"shall automatically convert into Common Stock on a one-to-one basis"

48 equal monthly installments technical

"vest in 48 equal monthly installments"

initial public offering financial

"immediately prior to the completion of the Issuer's initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did IAM CFO Michael Secora report owning?

Michael Secora reported direct ownership of 190,160 common shares and 61,342 Series B-3 convertible preferred shares. Of the common shares, 23,770 were issued under an early-exercise provision and vest in full on January 1, 2027. The preferred shares automatically convert one-for-one into common stock immediately before completion of the initial public offering.

What options did IAM CFO Michael Secora report?

He reported options covering 190,161 common shares at $7.31, expiring January 8, 2035, and options covering 9,508 common shares at $8.73, expiring March 3, 2036. The first option vests in 48 equal monthly installments beginning February 1, 2025; the second vests in 48 equal monthly installments beginning March 23, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/15/2026 - 08:46 PM EDT Accepted by SEC EDGAR 10/14/2026 - 06:40 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Secora Michael

(Last)

(First)

(Middle)

C/O IAMBIC THERAPEUTICS, INC.

5627 OBERLIN DRIVE, SUITE 120

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/14/2026

3. Issuer Name and Ticker or Trading Symbol
Iambic Therapeutics, Inc. [ IAM ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CFO & Chief Corp Dev Ofcr

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock⁽¹⁾	190,160	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series B-3 Convertible Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	61,342	⁽²⁾	D
Employee Stock Option (right to buy)	⁽³⁾	01/08/2035	Common Stock	190,161	$7.31	D
Employee Stock Option (right to buy)	⁽⁴⁾	03/03/2036	Common Stock	9,508	$8.73	D

Explanation of Responses:

1. Of the reported shares, 23,770 were issued pursuant to an early exercise provision and which vest in full on January 1, 2027.

2. Each share of Series B-3 Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

3. An option to purchase 380,322 shares was granted on January 8, 2025 and was exercised in part prior to the date on which the reporting person became subject to Section 16. The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest in 48 equal monthly installments beginning on February 1, 2025.

4. The shares subject to the option vest in 48 equal monthly installments beginning on March 23, 2026.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Sunny Chang, by power of attorney	10/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR